Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year

This article was originally published in RPM Report

Executive Summary

United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.

Related Content

Not So Random Selection: Medicare Agency Cuts "Churn" In Part D Enrollment
Medicare Market Shares: Why the Big Plans Don't Mind Losing Ground
iDoc: E-Prescribing Gains Momentum, But Roadblocks Remain
Medicare Rx in 2009: Re-Politicizing Drug Prices
Running Away from Part D: No Love for New Rx Benefit on Campaign Trail
The End of the PDP? What MemberHealth Means for Medicare Part D
Making Part D Stick: Lessons From the First Year of Medicare Rx
Medicare Part D Enters Phase 2: Land Rush Gives Way to Claim Jumping
Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention
Medicare Market Share: Drug Plan Starts With Big Four


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts